Adele M. Lehane

Adele M. Lehane

Auto-generated profile, based on publicly available information

Adele M. Lehane

Research School of Biology Australian National University Canberra 2601 Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2016 in Nature Communications
Verified
Journal Article
Open access
Maria Isabel Mendes VeigaMaria Isabel Mendes Veiga
Maria Isabel Mendes Veiga
SDSatish K. Dhingra
Satish K. Dhingra
PHPhilipp P. Henrich
Philipp P. Henrich
JSJudith Straimer
Judith Straimer
NGNina Gnädig
Nina Gnädig
DFDavid A. Fidock
David A. Fidock
Antimalarial chemotherapy, globally reliant on artemisinin-based combination therapies (ACTs), is threatened by the spread of drug resistance inPlasmodium falciparumparasites. Here we use zinc-finger nucleases to genetically modify the multidrug resistance-1 transporter PfMDR1 at amino acids 86 and 184, and demonstrate that the widely prevalent N86Y mutation augments resistance to the ACT partner drug amodiaquine and the former first-line agent chloroquine. In contrast, N86Y increases parasite susceptibility to the partner drugs lumefantrine and mefloquine, and the active artemisinin metabolite dihydroartemisinin. The PfMDR1 N86 plus Y184F isoform moderately reduces piperaquine potency in strains expressing an Asian/African variant of the chloroquine resistance transporter PfCRT. Mutations in both digestive vacuole-resident transporters are thought to differentially regulate ACT drug interactions with host haem, a product of parasite-mediated haemoglobin degradation. Global mapping of these mutations illustrates where the different ACTs could be selectively deployed to optimize treatment based on regional differences in PfMDR1 haplotypes.

1 November 2012 in Trends in Parasitology
Verified
Journal Article
Closed access
AEAndrea Ecker
Andrea Ecker
ALAdele M. Lehane
Adele M. Lehane
JCJérôme Clain
Jérôme Clain
DFDavid A. Fidock
David A. Fidock

16 December 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MJMaría Belén Jiménez-Díaz
María Belén Jiménez-Díaz
DEDaniel Ebert
Daniel Ebert
YSYandira Salinas
Yandira Salinas
APAnupam Pradhan
Anupam Pradhan
ALAdele M. Lehane
Adele M. Lehane
RGR. Kiplin Guy
R. Kiplin Guy
Significance: Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733 cleared parasites in vivo as quickly as artesunate by specifically inducing eryptosis/senescence in infected, treated erythrocytes. Although in vitro selection of pfatp4 mutants with (+)-SJ733 proceeded with moderate frequency, during in vivo selection of pbatp4 mutants, resistance emerged slowly and produced marginally resistant mutants with poor fitness. In addition, (+)-SJ733 met all other criteria for a clinical candidate, including high oral bioavailability, a high safety margin, and transmission blocking activity. These results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication.

28 July 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
WVWesley C Van Voorhis
Wesley C Van Voorhis
JAJohn H Adams
John H Adams
RARoberto Adelfio
Roberto Adelfio
VAVida Ahyong
Vida Ahyong
MAMyles H Akabas
Myles H Akabas
PWPaul A Willis
Paul A Willis
A major cause of the paucity of new starting points for drug discovery is the lack of interaction between academia and industry. Much of the global resource in biology is present in universities, whereas the focus of medicinal chemistry is still largely within industry. Open source drug discovery, with sharing of information, is clearly a first step towards overcoming this gap. But the interface could especially be bridged through a scale-up of open sharing of physical compounds, which would accelerate the finding of new starting points for drug discovery. The Medicines for Malaria Venture Malaria Box is a collection of over 400 compounds representing families of structures identified in phenotypic screens of pharmaceutical and academic libraries against the Plasmodium falciparum malaria parasite. The set has now been distributed to almost 200 research groups globally in the last two years, with the only stipulation that information from the screens is deposited in the public domain. This paper reports for the first time on 236 screens that have been carried out against the Malaria Box and compares these results with 55 assays that were previously published, in a format that allows a meta-analysis of the combined dataset. The combined biochemical and cellular assays presented here suggest mechanisms of action for 135 (34%) of the compounds active in killing multiple life-cycle stages of the malaria parasite, including asexual blood, liver, gametocyte, gametes and insect ookinete stages. In addition, many compounds demonstrated activity against other pathogens, showing hits in assays with 16 protozoa, 7 helminths, 9 bacterial and mycobacterial species, the dengue fever mosquito vector, and the NCI60 human cancer cell line panel of 60 human tumor cell lines. Toxicological, pharmacokinetic and metabolic properties were collected on all the compounds, assisting in the selection of the most promising candidates for murine proof-of-concept experiments and medicinal chemistry programs. The data for all of these assays are presented and analyzed to show how outstanding leads for many indications can be selected. These results reveal the immense potential for translating the dispersed expertise in biological assays involving human pathogens into drug discovery starting points, by providing open access to new families of molecules, and emphasize how a small additional investment made to help acquire and distribute compounds, and sharing the data, can catalyze drug discovery for dozens of different indications. Another lesson is that when multiple screens from different groups are run on the same library, results can be integrated quickly to select the most valuable starting points for subsequent medicinal chemistry efforts. Malaria leads to the loss of over 440,000 lives annually; accelerating research to discover new candidate drugs is a priority. Medicines for Malaria Venture (MMV) has distilled over 25,000 compounds that kill malaria parasites in vitro into a group of 400 representative compounds, called the "Malaria Box". These Malaria Box sets were distributed free-of-charge to research laboratories in 30 different countries that work on a wide variety of pathogens. Fifty-five groups compiled >290 assay results for this paper describing the many activities of the Malaria Box compounds. The collective results suggest a potential mechanism of action for over 130 compounds against malaria and illuminate the most promising compounds for further malaria drug development research. Excitingly some of these compounds also showed outstanding activity against other disease agents including fungi, bacteria, other single-cellular parasites, worms, and even human cancer cells. The results have ignited over 30 drug development programs for a variety of diseases. This open access effort was so successful that MMV has begun to distribute another set of compounds with initial activity against a wider range of infectious agents that are of public health concern, called the Pathogen Box, available now to scientific labs all over the world (www.PathogenBox.org).

1 January 2008 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
ALAdele M Lehane
Adele M Lehane
KSKevin J. Saliba
Kevin J. Saliba
Flavonoids are abundant plant phenolic compounds. More than 6000 have been identified to date, and some have been shown to possess antiparasitic activity. Here we investigate the effects of a range of common dietary flavonoids on the growth of two strains of the human malaria parasite Plasmodium falciparum.

15 September 2014 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
ALAdele M. Lehane
Adele M. Lehane
MRMelanie C. Ridgway
Melanie C. Ridgway
EBEileen Baker
Eileen Baker
KKKiaran Kirk
Kiaran Kirk